Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma - PubMed (original) (raw)
. 2013 Jan 15;119(2):293-303.
doi: 10.1002/cncr.27743. Epub 2012 Jul 18.
Kun-Ju Lin, Wu-Lung R Yang, Ya-Wen Kao, Tsung-Wen Chen, Shu-Chaou Chao, Peter Mu-Hsin Chang, Chun-Yu Liu, Cheng-Hwai Tzeng, Yee Chao, Ming-Han Chen, Chun-Nan Yeh, Chi-Ying F Huang
Affiliations
- PMID: 22810956
- DOI: 10.1002/cncr.27743
Free article
Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma
Ming-Huang Chen et al. Cancer. 2013.
Free article
Abstract
Background: Cholangiocarcinoma (CCA) is an aggressive tumor with a poor prognosis. There is no standard therapy for CCA, and novel drugs for treating refractory CCA need to be identified.
Methods: The authors hypothesized that, if a drug could reverse the gene expression signature of CCA, then it may inhibit the carcinogenesis of CCA and, hence, would be a potential therapeutic agent. Thus, the gene expression signatures from patients with CCA were queried using the bioinformatic method Connectivity Map, resulting in the enrichment of heat-shock protein 90 (HSP90) inhibitors with therapeutic potentials.
Results: Two HSP90 inhibitors, 17-AAG (tanespimycin) and the synthetic diarylisoxazole amide resorcinol NVP-AUY922, demonstrated potent antiproliferative activity in in vitro studies. In a thioacetamide-induced animal model, NVP-AUY922 also had antitumor activity and resulted in objective tumor regression. In addition, NVP-AUY922 reduced the expression of client oncoproteins involved in CCA oncogenesis and inhibited downstream proteins of both the phosphatidylinositol 3-kinase catalytic subunit α/v-akt murine thymoma viral oncogene homolog 1 protein kinase (PIK3/AKT) pathway and the v-Ki-ras2 Kirsten rat sarcoma viral oncogene/mitogen-activated protein kinase (KRAS/MAPK) pathway.
Conclusions: Preclinical data from the current study suggest that NVP-AUY922 may be an effective treatment option for patients with CCA.
Copyright © 2012 American Cancer Society.
Similar articles
- Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T; Australian Prostate Cancer BioResource; Tilley WD, Butler LM. Centenera MM, et al. Clin Cancer Res. 2012 Jul 1;18(13):3562-70. doi: 10.1158/1078-0432.CCR-12-0782. Epub 2012 May 9. Clin Cancer Res. 2012. PMID: 22573351 - Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN. Chen MH, et al. Oncotarget. 2014 May 15;5(9):2372-89. doi: 10.18632/oncotarget.1706. Oncotarget. 2014. PMID: 24796583 Free PMC article. - The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ, Lazenby M, Pepper CJ, Knapper S, Burnett AK. Walsby EJ, et al. Br J Haematol. 2013 Apr;161(1):57-67. doi: 10.1111/bjh.12215. Epub 2013 Jan 29. Br J Haematol. 2013. PMID: 23356405 - Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma.
Koprowski S, Sokolowski K, Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M. Koprowski S, et al. J Surg Res. 2015 Oct;198(2):434-40. doi: 10.1016/j.jss.2015.03.029. Epub 2015 Mar 19. J Surg Res. 2015. PMID: 25890434 Review. - Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
Zhang GF, Qiu L, Yang SL, Wu JC, Liu TJ. Zhang GF, et al. Biosci Rep. 2020 Mar 27;40(3):BSR20193353. doi: 10.1042/BSR20193353. Biosci Rep. 2020. PMID: 32140709 Free PMC article. Review.
Cited by
- Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach.
Janvilisri T, Leelawat K, Roytrakul S, Paemanee A, Tohtong R. Janvilisri T, et al. Dis Markers. 2015;2015:105358. doi: 10.1155/2015/105358. Epub 2015 Apr 28. Dis Markers. 2015. PMID: 26060332 Free PMC article. - A genomic signature approach to rescue ΔF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function.
Ramachandran S, Osterhaus SR, Karp PH, Welsh MJ, McCray PB Jr. Ramachandran S, et al. Am J Respir Cell Mol Biol. 2014 Sep;51(3):354-62. doi: 10.1165/rcmb.2014-0007OC. Am J Respir Cell Mol Biol. 2014. PMID: 24669817 Free PMC article. - Translational Bioinformatics for Cholangiocarcinoma: Opportunities and Challenges.
Qian F, Guo J, Jiang Z, Shen B. Qian F, et al. Int J Biol Sci. 2018 May 22;14(8):920-929. doi: 10.7150/ijbs.24622. eCollection 2018. Int J Biol Sci. 2018. PMID: 29989102 Free PMC article. Review. - Degradation of AZGP1 suppresses apoptosis and facilitates cholangiocarcinoma tumorigenesis via TRIM25.
Yun H, Jeong HR, Kim DY, You JE, Lee JU, Kang DH, Koh DI, Ryu YS, Bae S, Jin DH. Yun H, et al. J Cell Mol Med. 2024 Feb;28(3):e18104. doi: 10.1111/jcmm.18104. Epub 2024 Jan 6. J Cell Mol Med. 2024. PMID: 38183356 Free PMC article. - Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma.
Chen M, Qian C, Jin B, Hu C, Zhang L, Wang M, Zhou B, Zuo W, Huang L, Wang Y. Chen M, et al. Cancer Biol Ther. 2023 Dec 31;24(1):2162807. doi: 10.1080/15384047.2022.2162807. Cancer Biol Ther. 2023. PMID: 36647192 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous